SciELO - Scientific Electronic Library Online

 
vol.5 issue2Prospective assessment of clinical outcomes of transcatheter aortic valve implantation in a cohort of patients based on their risk profile author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


REC: Interventional Cardiology

On-line version ISSN 2604-7276Print version ISSN 2604-7306

Abstract

ELNAGGAR, Heba M et al. Transcatheter aortic valve implantation using Evolut PRO versus SAPIEN 3 valves: a randomized comparative trial. REC Interv Cardiol ES [online]. 2023, vol.5, n.2, pp.94-101.  Epub Mar 18, 2024. ISSN 2604-7276.  https://dx.doi.org/10.24875/recic.m22000348.

Introduction and objectives:

Advances made in transcatheter aortic valve implantation (TAVI) valvular technology have resulted in better outcomes and fewer complications compared with older generations. We studied the rate and determinants of paravalvular leak (PVL) using Evolut PRO vs SAPIEN 3 valves as well as other perioperative and in-hospital outcomes.

Methods:

A total of 110 consecutive patients with severe aortic stenosis scheduled for transfemoral TAVI were randomly selected to receive the SAPIEN 3 (N = 59) or the Evolut PRO valve (N = 51). Annular dimensions were determined by transesophageal echocardiography guided balloon sizing. The following postoperative and in-hospital endpoints were assessed: PVL, conduction defects, valve embolization, need for a second valve, annular rupture, stroke, vascular complications, acute kidney injury, and in-hospital mortality. We also studied the possible anatomical determinants of PVL.

Results:

There were no relevant baseline differences between the 2 groups regarding clinical and echocardiographic characteristics. In-hospital complications were comparable between both valves apart from a significantly higher rate of immediate postoperative PVL and at discharge (≥ grade II) between the Evolut PRO and the SAPIEN 3 valves (19.6% vs 6.8%) and (5.9% vs 1.7%), respectively. Of the anatomical variables described, the left ventricular outflow tract/ascending aorta angle, aortic angulation, and calcification had a significant impact on PVL in the Evolut PRO valves. The left ventricular outflow tract/ascending aorta angle revealed a negative correlation with implantation depth in the Evolut PRO valves but not in the SAPIEN 3 ones.

Conclusions:

Both valves demonstrated favorable comparable outcomes except for a significantly higher rate of PVL in patients implanted with Evolut PRO valves.

Keywords : Aortic stenosis; Transcatheter aortic valve implantation; TAVI; SAPIEN 3; Evolut PRO.

        · abstract in Spanish     · text in English | Spanish     · English ( pdf ) | Spanish ( pdf )